The estimated Net Worth of Stephen T Isaacs is at least $1.01 Millón dollars as of 15 September 2020. Stephen Isaacs owns over 32,481 units of Cerus stock worth over $572,290 and over the last 21 years Stephen sold CERS stock worth over $433,339.
Stephen has made over 38 trades of the Cerus stock since 2015, according to the Form 4 filled with the SEC. Most recently Stephen sold 32,481 units of CERS stock worth $77,630 on 15 September 2020.
The largest trade Stephen's ever made was exercising 72,051 units of Cerus stock on 8 March 2018 worth over $34,584. On average, Stephen trades about 19,568 units every 31 days since 2003. As of 15 September 2020 Stephen still owns at least 279,166 units of Cerus stock.
You can see the complete history of Stephen Isaacs stock trades at the bottom of the page.
Stephen's mailing address filed with the SEC is C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY, CA, 94710.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash y Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: